Barclays Initiates Coverage On Minimed Group with Overweight Rating, Announces Price Target of $26

Barclays analyst Matt Miksic has initiated coverage on Minimed Group (NASDAQ: MMED) with an Overweight rating. The firm has set a price target of $26 for the company's stock.